Edition:
United States

Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

1,486.25INR
30 Sep 2016
Change (% chg)

Rs17.95 (+1.22%)
Prev Close
Rs1,468.30
Open
Rs1,468.70
Day's High
Rs1,489.50
Day's Low
Rs1,458.80
Volume
860,417
Avg. Vol
1,220,101
52-wk High
Rs2,129.00
52-wk Low
Rs1,280.00

Select another date:

Thu, Sep 29 2016

BRIEF-Lupin gets FDA approval for generic Namenda XR capsules

* Receives FDA approval for Generic Namenda XR capsules Source text: http://bit.ly/2dgwkvs Further company coverage:

Indian shares fall more than 1 pct; Lupin down

Aug 10 Indian shares fell more than 1 percent on Wednesday, posting their worst fall in more than six weeks, as investors weighed whether a recent rally in equities may have been overdone, with drug maker Lupin Ltd down on concerns over its earnings outlook.

UPDATE 2-Lupin's Q1 profit boosted by lower tax rate

* Shares close down 5.08 pct in Mumbai (Adds management comments from analyst call, bullets; updates share move)

India's Lupin Q1 profit up 68 pct, beats estimates

MUMBAI, Aug 9 Lupin Ltd, India's third-largest drugmaker, reported a 68 percent rise in first-quarter profit, beating analysts' expectations.

BRIEF-Silver Range acquires Itchen Property near Lupin Mine

* Silver Range acquires Itchen Property near Lupin Mine Source text for Eikon: Further company coverage:

BRIEF-Silver range acquires Itchen Property near Lupin Mine

* Silver Range acquires Itchen Property near Lupin Mine Source text for Eikon: Further company coverage:

India's Lupin to buy 21 branded drugs from Japan's Shionogi

MUMBAI, Aug 2 Indian drugmaker Lupin Ltd said it had agreed to buy a portfolio of 21 drugs from Japan's Shionogi & Co Ltd for 15.4 billion yen ($150 million), expanding its presence in its third-largest market.

Lupin seeks to invalidate patent on Bausch & Lomb eye drug

Indian generic drugmaker Lupin Ltd is asking a court to invalidate a patent on Bausch & Lomb Inc's anti-inflammatory eye drug Prolensa as it seeks to make a generic version of the drug.

UPDATE 1-India's Lupin Q4 profit beats estimates as U.S. sales jump

* Q4 profit 8.07 bln rupees vs 6.78 bln rupees analysts expected

BRIEF-Lupin CEO says to focus on growing specialty business on the acquisitions front

* CEO Vinita Gupta says on the acquisitions front, focus will be to grow specialty business

Select another date: